CN1829525A - 用于生物防御的免疫疗法 - Google Patents

用于生物防御的免疫疗法 Download PDF

Info

Publication number
CN1829525A
CN1829525A CNA2004800215188A CN200480021518A CN1829525A CN 1829525 A CN1829525 A CN 1829525A CN A2004800215188 A CNA2004800215188 A CN A2004800215188A CN 200480021518 A CN200480021518 A CN 200480021518A CN 1829525 A CN1829525 A CN 1829525A
Authority
CN
China
Prior art keywords
antibody
antibody fragment
sequence
district
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800215188A
Other languages
English (en)
Chinese (zh)
Inventor
K·S·鲍迪什
S·弗雷德里克松
M·A·维尔德
丸山俊昭
M·J·诺兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CN1829525A publication Critical patent/CN1829525A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800215188A 2003-06-02 2004-05-26 用于生物防御的免疫疗法 Pending CN1829525A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/452,593 2003-06-02
US10/452,593 US20040258699A1 (en) 2002-02-11 2003-06-02 Immunotherapeutics for biodefense

Publications (1)

Publication Number Publication Date
CN1829525A true CN1829525A (zh) 2006-09-06

Family

ID=33551270

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800215188A Pending CN1829525A (zh) 2003-06-02 2004-05-26 用于生物防御的免疫疗法

Country Status (9)

Country Link
US (1) US20040258699A1 (https=)
EP (1) EP1648487A2 (https=)
JP (1) JP2006526639A (https=)
KR (1) KR20060031803A (https=)
CN (1) CN1829525A (https=)
AU (1) AU2004247034A1 (https=)
CA (1) CA2527843A1 (https=)
IL (1) IL172231A0 (https=)
WO (1) WO2004110362A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172734A (zh) * 2013-04-07 2013-06-26 中国人民解放军南京军区军事医学研究所 人源抗炭疽毒素保护性抗原中和抗体Fab及应用
CN104628853A (zh) * 2015-02-06 2015-05-20 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395657B1 (en) * 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
WO2005007804A2 (en) * 2003-04-10 2005-01-27 President And Fellows Of Harvard College Anthrax conjugate vaccine and antibodies
CA2560759A1 (en) * 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
WO2008063147A2 (en) * 2005-03-31 2008-05-29 The General Hospital Corporation Anthrax polypeptide binding
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
US7794732B2 (en) 2006-05-12 2010-09-14 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
EP2246426A4 (en) * 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB0812316D0 (en) * 2008-07-07 2008-08-13 Secr Defence Antibody
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
TWI606834B (zh) * 2014-10-24 2017-12-01 國立陽明大學 缺氧培養之間葉幹細胞用於修復血管內皮細胞的應用
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
CN109134647B (zh) 2018-08-28 2020-08-04 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
CN109081869B (zh) 2018-08-28 2022-06-03 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
MX2024000957A (es) * 2021-07-22 2024-02-08 Us Gov Sec Navy Anticuerpos de dominio unico que se unen y neutralizan el virus de la encefalitis equina venezolana.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407443A1 (en) * 2000-05-04 2001-11-08 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
JP2006503547A (ja) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 生物兵器防衛のための免疫療法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172734A (zh) * 2013-04-07 2013-06-26 中国人民解放军南京军区军事医学研究所 人源抗炭疽毒素保护性抗原中和抗体Fab及应用
CN104628853A (zh) * 2015-02-06 2015-05-20 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用
CN104628853B (zh) * 2015-02-06 2017-10-10 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用

Also Published As

Publication number Publication date
EP1648487A2 (en) 2006-04-26
AU2004247034A1 (en) 2004-12-23
IL172231A0 (en) 2006-04-10
JP2006526639A (ja) 2006-11-24
KR20060031803A (ko) 2006-04-13
US20040258699A1 (en) 2004-12-23
CA2527843A1 (en) 2004-12-23
WO2004110362A3 (en) 2005-07-28
WO2004110362A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
CN1829525A (zh) 用于生物防御的免疫疗法
US20040009178A1 (en) Immunotherapeutics for biodefense
CN1267452C (zh) 单克隆抗体、抗原和恶性疾病的诊断和治疗
CN116063464A (zh) 冠状病毒的抗体或其抗原结合片段
CN1489474A (zh) 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
CN1914226A (zh) SARS－CoV抗体及其使用方法
CN111848786B (zh) 一种单克隆抗体、其制备方法及用途
CN114292327B (zh) 一种广谱新型冠状病毒的人源抗体及其应用
CN1526072A (zh) 埃-巴二氏病毒(ebv)肿瘤相关潜伏膜蛋白的胞外结构域的鉴定方法和与之反应的抗体试剂的选择方法
CN114456264A (zh) 一种新型冠状病毒稀有广谱表位的人源抗体及其应用
CN1768078A (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
CN101045751A (zh) 人源抗a型肉毒神经毒素基因工程抗体及其制备方法与用途
CN1882610A (zh) 产生阻断人细胞因子生物活性的人抗体的高产量方法
CN111454337B (zh) 1型和3型鸭甲肝病毒共有的中和性模拟抗原表位及其应用
CN1305904C (zh) 人源的抗破伤风毒素单克隆抗体的制备和应用
CN114395034B (zh) 一种高效中和新型冠状病毒的人源抗体及其应用
Ng et al. Cancer Antibody Engineering: Comparison of Mammalian, Yeast, Bacterial, Plants, Cell-free and Hybridoma Expression Systems
WO2022105818A1 (en) Combinations of antibodies and bispecific antibodies comprising antigen-binding specifically recognizing pseudomonas pcrv and psl
CN1324049C (zh) 人源抗sars冠状病毒基因工程抗体
Tabll et al. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22+ B cells
CN119192358B (zh) 单克隆抗体及其应用
CN116063469B (zh) 一种寨卡病毒中和性纳米抗体及其制备方法与应用
CN109957013A (zh) 抗h7n9全人源单克隆抗体7o2及其制法与应用
CN109957011A (zh) 抗h7n9全人源单克隆抗体6e9及其制法与应用
Kgagudi Delineating Antibody Responses Elicited by Four SARS-CoV-2 Variants against the Mu Variant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication